fbpx

molecules of the month

ENT-01

oral ⍺-synuclein aggregation inhibitor

completed Ph. IIb for PD + constipation

natural product

Sci. Adv., 16 November 2022

Enterin Inc., Philadelphia, PA

ENT-01 chemical structure oral ⍺-synuclein aggregation inhibitor- Enterin Inc., Philadelphia, PA
3 mins read

An old molecule and an old target come together. Squalamine was originally discovered in 1993 as an antimicrobial from the liver of the dogfish shark. It’s had a long and interesting history, investigated by Magainin/Genaera as a Ph. II antiangiogenic drug candidate for cancer and as a Ph. III opthalmic candidate for macular degeneration. One of the scientists from Magainin, Michael Zasloff, is now the co-founder and CSO of Enterin, a company trying to develop squalamine as an oral, non-systemic drug for Parkinson’s disease. The Parkinson’s disease hypothesis. α-synuclein aggregation is a hallmark of Parkinson’s disease (PD) and other synucleinopathies. α-synuclein aggregates are neurotoxic, but targeting α-synuclein directly is challenging due to its relatively small size (14 kDa), unclear but…


request a trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.

Interested in learning more? Submit this form to request a trial.


already a member? log in: